<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/E1649C06-DC81-4A08-8A23-F5B65BB6C670"><gtr:id>E1649C06-DC81-4A08-8A23-F5B65BB6C670</gtr:id><gtr:name>Babraham Institute</gtr:name><gtr:department>UNLISTED</gtr:department><gtr:address><gtr:line1>Babraham Research Campus</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:line5>Cambridgeshire</gtr:line5><gtr:postCode>CB22 3AT</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E1649C06-DC81-4A08-8A23-F5B65BB6C670"><gtr:id>E1649C06-DC81-4A08-8A23-F5B65BB6C670</gtr:id><gtr:name>Babraham Institute</gtr:name><gtr:address><gtr:line1>Babraham Research Campus</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:line5>Cambridgeshire</gtr:line5><gtr:postCode>CB22 3AT</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/C0A7056F-E319-488D-BC7B-EB4514B543F8"><gtr:id>C0A7056F-E319-488D-BC7B-EB4514B543F8</gtr:id><gtr:firstName>Simon</gtr:firstName><gtr:otherNames>Jonathan</gtr:otherNames><gtr:surname>Cook</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=BBS%2FE%2FB%2F0000H242"><gtr:id>F9952858-AD23-4CD7-B65E-7BB0B65791FA</gtr:id><gtr:title>Role of ERK5 in cell transformation and P53 regulation</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>BBS/E/B/0000H242</gtr:grantReference><gtr:abstractText>The behaviour of all cells is controlled by a range of environmental factors and this is true during development in the embryo (responding to developmental signals), in the adult organism (responding to environmental changes) and in disease. Environmental changes trigger the activation of biochemical signal pathways inside the cell that act to coordinate the cellular response. These signal pathways are frequently mutated in diseases such as cancer and may represent attractive drug targets. One such signal pathway leads to the activation of an enzyme called ERK5. In this project we aim to understand how ERK5 controls processes such as cell division, cell survival and cell movement. In doing so we hope to better understand the normal function of ERK5 but also to determine if ERK5 is a good drug target in cancer.</gtr:abstractText><gtr:fund><gtr:end>2012-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/2512EF1C-401B-4222-9869-A770D4C5FAC7"><gtr:id>2512EF1C-401B-4222-9869-A770D4C5FAC7</gtr:id><gtr:name>BBSRC</gtr:name></gtr:funder><gtr:start>2009-04-01</gtr:start><gtr:type>EXPENDITURE_PROJECTED</gtr:type><gtr:valuePounds>80887</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Newcastle University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Northern Institute for Cancer Research Newcastle</gtr:department><gtr:description>Newcastle/CRT/MRC ERK5</gtr:description><gtr:id>61FC3920-CE81-4AA8-AA36-66FDADEC6735</gtr:id><gtr:impact>One manuscript published; a second in preparation; further research funding application submitted; identification of ERK5 inhibitors</gtr:impact><gtr:outcomeId>56e131d05bce23.64635261-1</gtr:outcomeId><gtr:partnerContribution>High throughput screening and follow up testing to identify ERK5 inhibitors</gtr:partnerContribution><gtr:piContribution>We have established a cell based assay that can be used to monitor ERK5 activity and screen for ERK5 inhibitors</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Science Open Day</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>E199C0F7-2E07-4205-8718-AE4D91949C64</gtr:id><gtr:impact>Students visited the lab and undertook small lab-based proejcts supervised by students/post-docs and myself. I explained the research that we do and discussed ethical issues such as the use of animals in research.
This precipitated excellent discussion and dialogue.

We received excellent feedback from the schools involved and requests for further outreach activities</gtr:impact><gtr:outcomeId>546f1146bc7243.35670753</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2013,2014,2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>In conversation with the Babraham Institute - part of Cambridge Science Festival</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>DCFC529E-02C0-4A8B-A73B-6B55BFD0D2FF</gtr:id><gtr:impact>1:1 dialogue with general public (open invitation but registration required for numbers). 
Evening reception in which we explain our science and answer questions
Part of a programme of events for the annual Cambridge Science Festival</gtr:impact><gtr:outcomeId>58c6c8ec91ae08.38724308</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Visits by Teachers</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>B4D24030-FD7E-492E-8796-4EF76BFC4320</gtr:id><gtr:impact>I hosted two 6th form Biology teachers (one PhD trained, the other MSc trained) who were visiting my Institution during Half Term to update their knowledge as part of their CPD</gtr:impact><gtr:outcomeId>56c1e8c3788c99.07519338</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>341874</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BBSRC Response mode project grant</gtr:description><gtr:end>2019-07-02</gtr:end><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:fundingRef>BB/N015886/1</gtr:fundingRef><gtr:id>690EDFB8-112B-44C9-AB48-B9E965A56BC9</gtr:id><gtr:outcomeId>58c92b509b1de2.41851432</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2016-07-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs><gtr:impactSummaryOutput><gtr:description>Our findings have contributed to further collaborations with a consortium of academic and industrial scientists aimed at developing ERK5 inhibitors as drugs</gtr:description><gtr:firstYearOfImpact>2012</gtr:firstYearOfImpact><gtr:id>361D43EB-8D0F-4ACF-A472-8A930C4ACC13</gtr:id><gtr:impactTypes><gtr:impactType>Economic</gtr:impactType></gtr:impactTypes><gtr:outcomeId>56e002b4b931c1.55209682</gtr:outcomeId><gtr:sector>Healthcare,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:impactSummaryOutput></gtr:impactSummaryOutputs><gtr:intellectualPropertyOutputs/><gtr:keyFindingsOutput><gtr:description>We have shown that the ERK5 pathway is not required for proliferation/division or survival of diverse cell types. Rather ERK5 signalling control cell motility and our preliminary results suggest that it may control a differentiation process called epithelial-to-mesenchymal transition.</gtr:description><gtr:exploitationPathways>Our results have implications for other academics interested in ERK5 biology but also for scientists in the phamraceutical sector who are developing ERK5 inhibitors as drugs for various diseases. Indeed, we have initiated further collaborations in this area with both academics and industrial scientists.</gtr:exploitationPathways><gtr:id>0076F53C-ABFB-40E6-9676-CF6FB2716D59</gtr:id><gtr:outcomeId>56e002460082f1.99991775</gtr:outcomeId><gtr:sectors><gtr:sector>Education,Healthcare,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:sectors></gtr:keyFindingsOutput><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs><gtr:researchDatabaseAndModelOutput><gtr:description>We have generated an Illumina mRNA array gene expression data set in which we have compared WT and ERK5 KO immortalised MEFs</gtr:description><gtr:id>3F920B1E-6F17-43EF-8200-F55C2EC2167A</gtr:id><gtr:impact>The results of this work have afforded new lines of enquiry and new directions for our research and have led to further research funding applications including BB/N015886/1

It will also lead to primary research publications and the results will be of interest to collaborators in the Pharma sector</gtr:impact><gtr:outcomeId>58ca5cba7eb148.28063709</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>ERK5 WT and KO gene data set</gtr:title><gtr:type>Database/Collection of data</gtr:type></gtr:researchDatabaseAndModelOutput></gtr:researchDatabaseAndModelOutputs><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>A panel of mutants of ERK5 have been generated that are defective for ERK5 kinase inhibitor binding. These mutants no longer exhibit paradoxical activation of ERK5 transcriptional transactivation domain (TAD) by ERK5 kinase inhibitors, confirming that the TAD activating function is due to 'on target' activity of the inhibitors.</gtr:description><gtr:id>A32A964C-D42A-4573-9020-CA8D1D922B2F</gtr:id><gtr:impact>The wider impact of this is too early to say. These tools have important implications for understanding the role of ERK5 in any and all biological responses in which ERK is implicated as they allow separation of ERK5 kinase and TAD activities.</gtr:impact><gtr:outcomeId>58ca545591be13.94589629</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>ERK5 mutants</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>A method for assessing the cellular activity of the ERK5 protein kinase</gtr:description><gtr:id>33A70744-90AB-4A3E-B8BE-7A1E8860FA11</gtr:id><gtr:impact>It has facilitated a joint academic/pharma ERK5 drug discovery project
It has also facilitated academic research in this area leading to one research publication and a second in preparation</gtr:impact><gtr:outcomeId>56e132e486df49.85844616</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>ERK5 cell based assay</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2013</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>3212F34A-1E12-4078-9E27-2D5D3A9CE741</gtr:id><gtr:title>Tumor cells with KRAS or BRAF mutations or ERK5/MAPK7 amplification are not addicted to ERK5 activity for cell proliferation.</gtr:title><gtr:parentPublicationTitle>Cell cycle (Georgetown, Tex.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aa64c866dd997fe62bf344fb5f87e0de"><gtr:id>aa64c866dd997fe62bf344fb5f87e0de</gtr:id><gtr:otherNames>Lochhead PA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1551-4005</gtr:issn><gtr:outcomeId>56e1278895d507.35973881</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>69318144-D6E9-4840-B336-5ADFA489E8B5</gtr:id><gtr:title>CDK1, not ERK1/2 or ERK5, is required for mitotic phosphorylation of BIMEL.</gtr:title><gtr:parentPublicationTitle>Cellular signalling</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/78262698bd2c49ee0e8ffdae19911d01"><gtr:id>78262698bd2c49ee0e8ffdae19911d01</gtr:id><gtr:otherNames>Gilley R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0898-6568</gtr:issn><gtr:outcomeId>546f51089a20b5.37391864</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9F0E9E9D-0F4D-4B33-893A-B8849343A080</gtr:id><gtr:title>ERK1/2, but not ERK5, is necessary and sufficient for phosphorylation and activation of c-Fos.</gtr:title><gtr:parentPublicationTitle>Cellular signalling</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/78262698bd2c49ee0e8ffdae19911d01"><gtr:id>78262698bd2c49ee0e8ffdae19911d01</gtr:id><gtr:otherNames>Gilley R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0898-6568</gtr:issn><gtr:outcomeId>56c1c45c9bb780.69584885</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3571A133-5DDE-45C3-8402-C44FB40FE6A3</gtr:id><gtr:title>ERK5 and its role in tumour development.</gtr:title><gtr:parentPublicationTitle>Biochemical Society transactions</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aa64c866dd997fe62bf344fb5f87e0de"><gtr:id>aa64c866dd997fe62bf344fb5f87e0de</gtr:id><gtr:otherNames>Lochhead PA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0300-5127</gtr:issn><gtr:outcomeId>546f51094126d6.06607301</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A0CC0B5F-1473-4F9C-907F-4D7A9C2EB0C8</gtr:id><gtr:title>Stimulating translational research: several European life science institutions put their heads together.</gtr:title><gtr:parentPublicationTitle>Trends in molecular medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a8479b792c385ceeaa8f7e0f8f5b7482"><gtr:id>a8479b792c385ceeaa8f7e0f8f5b7482</gtr:id><gtr:otherNames>Bentires-Alj M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1471-4914</gtr:issn><gtr:outcomeId>56459b1d19cd42.75752579</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">BBS/E/B/0000H242</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>